natur
clinic
care
bioemerg
present
distinct
ethic
oper
challeng
patient
care
research
press
concern
onset
bioemerg
alway
implement
clinic
public
health
measur
mitig
impact
stop
spread
diseas
research
still
need
support
goal
improv
capac
respond
next
threat
research
within
context
contain
care
ie
patient
care
within
clinic
biocontain
unit
remain
rel
new
domain
novel
unexpect
challeng
present
research
opportun
approach
new
bioemerg
challeng
vari
greatli
depend
type
research
conduct
understand
basic
broad
principl
human
subject
research
relev
studi
conduct
acut
care
set
well
grow
experi
investig
uniqu
set
develop
inform
foundat
contain
care
investig
recent
pandem
threat
sever
acut
respiratori
syndrom
sar
avian
influenza
pandem
influenza
ebola
viru
diseas
outbreak
highlight
challeng
conduct
clinic
research
diseas
outbreak
particularli
involv
novel
emerg
pathogen
particularli
limit
systemat
highqual
data
avail
moreov
debat
arisen
regard
ethic
basi
clinic
public
health
research
conduct
emerg
research
opportun
bioemerg
ampl
number
consider
must
taken
account
ensur
patient
public
care
worker
safeti
conduct
effect
research
environ
requir
make
distinct
public
health
practic
oper
respons
sever
research
activ
conduct
bioemerg
chapter
focu
primarili
clinic
research
particularli
relat
human
subject
particip
bioemerg
among
variou
type
clinic
research
treatment
studi
like
gener
involv
analyz
effect
countermeasur
therapeut
intervent
affect
atrisk
individu
addit
research
relat
vaccin
postexposur
prophylaxi
develop
trial
atrisk
popul
healthcar
worker
may
conduct
goal
develop
therapeut
tool
prevent
futur
outbreaksinfect
exampl
research
may
involv
collect
biospecimen
use
futur
research
effort
quarantin
contain
research
understand
infect
transmiss
dynam
research
specimen
highli
valuabl
inform
downstream
laboratori
analysi
better
understand
infecti
diseas
final
diagnost
screen
research
seek
detect
specif
diseas
individu
afflict
studi
offer
new
inform
critic
compon
research
outbreak
pandem
focus
prevent
spread
infect
research
necessari
effect
clinic
public
health
respons
beyond
clinic
research
oper
implement
research
bioemerg
often
focus
realtim
improv
clinic
health
system
respons
may
includ
epidemiolog
studi
focus
identif
caus
effect
simpli
case
specif
infect
may
includ
look
pattern
outbreak
improv
respons
mani
case
may
constitut
human
subject
research
research
must
conduct
manner
minim
risk
particip
investig
must
design
protocol
limit
potenti
harm
must
monitor
subject
throughout
protocol
prepar
adjust
studi
paramet
design
assur
subject
expos
unnecessari
risk
time
protocol
must
design
maxim
possibl
direct
subject
benefit
gener
scientif
valu
may
particularli
difficult
set
diseas
process
unknown
natur
histori
use
intervent
unproven
mani
case
theoret
efficaci
research
ethic
principl
belmont
report
hh
fda
regul
requir
select
subject
must
fair
primarili
base
scientif
valid
also
distribut
risk
benefit
equit
particularli
true
case
therapeut
research
bioemerg
avail
intervent
limit
prioriti
dictat
ethic
principl
fair
countri
among
popul
within
countri
ie
distribut
justic
likelihood
posit
impact
individu
public
health
outcom
addit
investig
consid
issu
reciproc
social
use
reciproc
refer
oblig
healthcar
worker
pandem
oblig
societi
return
accept
healthcar
provid
risk
take
care
patient
highli
communic
diseas
engend
reciproc
duti
part
commun
social
use
refer
idea
healthcar
worker
preferenti
access
prophylaxi
treatment
would
directli
associ
continu
abil
healthcar
system
provid
intervent
everybodi
els
investig
must
design
studi
irb
must
also
assur
subject
provid
voluntari
valid
inform
consent
particip
research
consent
base
adequ
understand
inform
present
manner
minim
possibl
confus
coercion
undu
influenc
condit
surround
bioemerg
easili
lend
provis
time
thought
consider
subject
investig
sure
risk
associ
intervent
much
less
clearli
explain
subject
subject
may
ill
meaning
practic
particip
process
inform
consent
particularli
special
pathogen
ebola
viru
contribut
substanti
cognit
impair
circumst
may
necessari
util
legal
author
repres
provid
consent
accur
permiss
patient
particip
research
waiver
consent
particip
research
allow
fda
hh
regul
limit
circumst
fda
regul
allow
inform
consent
may
waiv
investig
physician
otherwis
particip
clinic
investig
certifi
write
human
subject
confront
lifethreaten
situat
necessit
use
test
articl
inform
consent
obtain
subject
inabl
commun
obtain
legal
effect
consent
subject
time
suffici
obtain
consent
subject
legal
repres
avail
altern
method
approv
gener
recogn
therapi
provid
equal
greater
likelihood
save
life
subject
potenti
applic
treatment
studi
novel
intervent
incapacit
person
bioemerg
waiver
would
appropri
collect
biospecimen
epidemiolog
studi
addit
fda
allow
except
inform
consent
requir
emerg
research
howev
conduct
research
regul
requir
extens
prepar
investig
irb
respons
exampl
regul
requir
consult
repres
public
disclosur
commun
clinic
investig
conduct
subject
drawn
prior
initi
clinic
investig
also
requir
public
disclosur
suffici
inform
follow
complet
clinic
investig
appris
commun
research
studi
well
regul
requir
independ
data
monitor
committe
exercis
oversight
clinic
investig
addit
protect
make
use
method
unsuit
bioemerg
situat
import
stress
consent
particip
therapi
research
bioemerg
differ
consent
clinic
treatment
set
clinic
set
patient
incapacit
need
lifesav
intervent
provid
consent
impli
consent
accept
practic
impli
consent
valid
research
set
fda
regul
use
fdaunapprov
drug
devic
biolog
human
subject
requir
except
limit
circumst
prior
irb
approv
use
also
requir
inform
consent
except
describ
usual
process
requir
fda
grant
investig
new
drug
ind
investig
devic
exempt
ide
design
allow
drug
devic
use
legal
market
consid
use
unapprov
drug
commonli
investig
sponsor
submit
ind
propos
studi
unapprov
drug
approv
product
new
indic
new
patient
popul
contrast
emerg
use
ind
allow
fda
author
use
experiment
drug
emerg
situat
allow
time
usual
ind
process
also
use
patient
meet
criteria
exist
studi
protocol
approv
studi
protocol
exist
final
treatment
ind
may
submit
experiment
drug
show
promis
clinic
test
seriou
immedi
lifethreaten
condit
final
clinic
work
conduct
fda
review
take
place
research
util
drug
three
type
ind
requir
irb
approv
describ
irb
must
determin
criteria
approv
met
inform
consent
obtain
right
welfar
subject
protect
specif
limit
circumst
unapprov
drug
may
use
without
prospect
irb
approv
fda
regul
allow
use
investig
drug
biolog
product
lifethreaten
situat
standard
accept
treatment
avail
suffici
time
obtain
irb
approv
regul
allow
one
emerg
use
test
articl
without
prospect
irb
review
subsequ
use
investig
product
institut
prospect
irb
review
approv
fda
acknowledg
howev
would
inappropri
deni
emerg
treatment
ond
individu
obstacl
irb
suffici
time
conven
meet
review
issu
even
emerg
use
investig
requir
obtain
inform
consent
subject
subject
legal
author
repres
except
describ
second
mechan
use
unapprov
drug
bioemerg
involv
issuanc
emerg
use
author
eua
fda
may
allow
unapprov
medic
product
unapprov
use
approv
medic
product
use
emerg
diagnos
treat
prevent
seriou
lifethreaten
diseas
condit
caus
biolog
agent
like
ebola
anthrax
adequ
approv
avail
altern
eua
must
issu
commission
base
determin
secretari
homeland
secur
defens
hh
domest
militari
public
health
emerg
exist
product
approv
eua
must
meet
lower
standard
effect
must
address
seriou
lifethreaten
diseas
condit
must
favor
riskbenefit
assess
must
adequ
approv
avail
altern
eua
valid
year
date
declar
emerg
long
emerg
effect
whichev
shorter
use
drug
devic
eua
requir
neither
irb
review
inform
consent
though
fact
sheet
healthcar
provid
recipi
requir
discuss
irb
respons
protect
right
welfar
human
subject
research
respons
share
obvious
investig
irb
must
determin
regulatori
criteria
approv
met
typic
irb
receiv
written
applic
describ
research
well
investig
descript
investig
assur
risk
minim
risk
benefit
relationship
accept
subject
select
equit
irb
review
inform
along
full
sponsor
protocol
inform
consent
document
investig
brochur
addit
materi
full
conven
meet
due
deliber
board
may
approv
research
condit
upon
minor
modif
return
applic
investig
clarif
modif
need
satisfi
regulatori
criteria
approv
addit
review
approv
committe
scientif
review
pharmaci
therapeut
sponsor
program
contract
institut
biosafeti
may
need
eventu
protocol
approv
investig
may
begin
recruit
potenti
subject
process
thought
protect
typic
lend
urgent
timelin
associ
bioemerg
sever
approach
problem
util
exampl
ethic
review
board
san
msf
describ
process
review
approv
gener
pathogen
intervent
agnost
master
research
protocol
advanc
bioemerg
detail
relat
specif
outbreak
amend
protocol
known
anoth
approach
creation
nation
region
central
irb
focu
public
health
emerg
includ
bioemerg
hh
public
health
emerg
research
review
board
pherrb
one
bodi
serv
irb
record
institut
state
health
depart
academ
medic
center
commun
hospit
engag
conduct
protocol
third
approach
util
rapid
respons
irb
develop
univers
nebraska
medic
center
unmc
fulli
constitut
irb
creat
allow
review
clinic
protocol
expedit
timelin
util
extens
prereview
protocol
consent
document
iter
process
close
collabor
investig
unmc
rapid
respons
irb
rrirb
use
success
review
research
protocol
associ
sever
investig
drug
intervent
target
patient
ebola
viru
diseas
hospit
nebraska
biocontain
unit
unmcnebraska
medicin
rrirb
unmc
also
serv
central
irb
entir
nation
ebola
train
educ
center
netec
special
pathogen
research
network
consist
unmc
nine
addit
netec
region
treatment
center
site
facilit
singl
irb
process
network
util
relianc
agreement
model
nih
smart
streamlin
multisit
acceler
resourc
trial
irb
platform
bioemerg
standard
approach
gener
evid
inform
medic
practic
may
appropri
feasibl
grow
interest
develop
adapt
protocol
allow
flexibl
adapt
studi
design
use
ongo
data
analysi
model
inform
design
structur
approach
twofold
benefit
increas
likelihood
obtain
usabl
highqual
data
variabl
fastpac
studi
environ
reduc
costprohibit
price
tag
tradit
clinic
trial
addit
trial
network
form
around
specif
clinic
area
interest
capit
exist
research
infrastructur
becom
increasingli
common
develop
share
burden
research
infrastructur
need
across
multipl
site
often
accomplish
common
master
model
protocol
central
irb
central
biorepositori
innov
approach
share
resourc
conduct
clinic
research
may
necessari
collect
biospecimen
human
subject
specimen
may
collect
clinic
purpos
use
inform
research
studi
may
collect
specif
research
purpos
common
rule
govern
collect
biolog
specimen
live
subject
addit
specif
state
organ
may
rule
regard
human
sampl
specimen
collect
retriev
practic
vari
depend
type
research
activ
natur
specimen
particular
infecti
diseas
patient
exampl
serum
sampl
highli
virem
ebola
viru
diseas
patient
address
handl
differ
nasal
swab
patient
unidentifi
influenzalik
ill
sever
best
practic
guidanc
document
regard
handl
research
specimen
inform
see
laboratori
chapter
text
chap
collect
option
store
maintain
biolog
specimen
associ
data
unspecifi
futur
use
biorepositori
biorepositori
collect
human
biolog
materi
andor
data
intend
use
research
purpos
even
purpos
yet
known
data
specimen
may
identifi
deidentifi
either
code
anonym
process
especi
use
bioemerg
patient
abl
enrol
research
studi
may
sporad
small
number
ohrp
provid
specif
guidanc
use
identifi
exist
specimen
data
guidanc
code
privat
inform
specimen
use
research
repositori
activ
involv
three
compon
collect
storag
distribut
materi
andor
data
specif
irb
approv
continu
oversight
requir
bank
specimen
decis
store
specimen
data
futur
use
approv
advanc
collect
feder
regul
requir
separ
consent
storag
biolog
materi
subsequ
research
use
identifi
materi
may
requir
addit
inform
consent
subject
altern
consent
provid
time
bank
inform
specimen
may
suffici
descript
store
specimen
would
use
ie
consent
use
may
alreadi
obtain
addit
permiss
would
requir
final
separ
consent
use
specimen
could
waiv
research
minim
risk
affect
right
welfar
subject
research
practic
carri
addit
consent
requir
hh
regul
cfr
respons
investig
maintain
protect
human
subject
record
specimen
result
data
properli
destroy
feder
regul
requir
research
data
retain
least
year
complet
research
howev
mani
institut
minimum
amount
time
keep
data
upon
complet
research
import
awar
local
requir
storag
necessari
appropri
destruct
data
specimen
long
research
guarante
research
data
secur
kept
indefinit
note
collabor
necessari
effect
research
mani
bioemerg
often
time
diseas
may
rare
case
may
sporad
particularli
earli
emerg
creat
uniqu
challeng
around
protect
privaci
human
subject
particularli
given
high
level
media
attent
surround
event
exampl
ebola
viru
diseas
outbreak
public
awar
name
individu
treat
usa
formal
measur
protect
maintain
patient
privaci
alway
follow
may
suffici
context
awar
critic
reduc
risk
inadvert
particip
identif
goal
research
inform
generaliz
knowledg
research
data
may
critic
respons
context
unfold
public
health
emerg
although
publish
data
vital
research
process
may
delay
dissemin
find
potenti
benefici
chang
clinic
practic
public
health
action
wake
ebola
outbreak
world
health
organ
issu
consensu
statement
note
need
effici
effect
share
data
result
public
health
emerg
follow
sever
journal
made
sweep
chang
improv
research
abil
share
data
without
neg
impact
abil
publish
result
manuscript
conduct
research
bioemerg
investig
cogniz
need
time
inform
share
public
formal
result
conflict
aris
among
studi
team
member
regard
prioriti
approach
area
discuss
dissemin
plan
occur
earli
develop
research
studi
whenev
possibl
research
respons
maintain
public
confid
uphold
trust
appropri
conduct
research
especi
import
role
clinician
scientist
stake
particularli
high
context
bioemerg
set
opportun
conduct
clinic
novel
critic
research
also
consider
challeng
affect
popul
inher
vulner
aspect
conduct
research
emerg
environ
challeng
care
adher
high
standard
set
human
subject
research
help
ensur
right
welfar
individu
protect
bioemerg
person
maintain
trust
research
relationship
process
